Tempus AI (NASDAQ:TEM) CEO Sells $49,000.00 in Stock

Tempus AI, Inc. (NASDAQ:TEM) CEO Ryan Fukushima sold 700 shares of the firm’s stock in a transaction that occurred on Wednesday, September 16th. The shares were sold at an average price of $70.00, for a total value of $49,000.00. Following the transaction, the chief executive officer owned 15,874 shares of the company’s stock, valued at $1,111,180. This represents a 4.22% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ryan Fukushima also recently made the following trade(s):

• On Friday, August 21st, Ryan Fukushima sold 14,286 shares of Tempus AI stock. The stock was sold at an average price of $70.00, for a total value of $1,000,020.00.
• On Tuesday, August 18th, Ryan Fukushima sold 41,095 shares of Tempus AI stock. The stock was sold at an average price of $49.61, for a total transaction of $2,038,722.95.
• On Friday, August 7th, Ryan Fukushima sold 20,000 shares of Tempus AI stock. The stock was sold at an average price of $50.04, for a total transaction of $1,000,800.00.
• On Monday, August 3rd, Ryan Fukushima sold 23,818 shares of Tempus AI stock. The shares were sold at an average price of $46.19, for a total value of $1,100,153.42.
• On Wednesday, July 8th, Ryan Fukushima sold 33,284 shares of Tempus AI stock. The shares were sold at an average price of $57.39, for a total value of $1,910,168.76.
• On Monday, July 6th, Ryan Fukushima sold 10,000 shares of Tempus AI stock. The stock was sold at an average price of $60.00, for a total value of $600,000.00.

Tempus AI Trading Down 3.1%

Shares of NASDAQ TEM traded down $2.52 during mid-day trading on Friday, reaching $77.84. The company had a trading volume of 9,310,212 shares, compared to its average volume of 7,226,184. The stock has a market cap of $14.04 billion, a price-to-earnings ratio of -54.06 and a beta of 3.72. The company has a current ratio of 3.30, a quick ratio of 3.16 and a debt-to-equity ratio of 3.06. Tempus AI, Inc. has a 52 week low of $40.77 and a 52 week high of $104.32. The business’s 50-day moving average is $57.19 and its 200-day moving average is $52.90.

Tempus AI (NASDAQ:TEM) last issued its earnings results on Thursday, July 30th. The company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.10. The business had revenue of $382.49 million for the quarter, compared to analyst estimates of $379.69 million. Tempus AI had a negative net margin of 17.77% and a negative return on equity of 50.28%. The company’s quarterly revenue was up 21.6% compared to the same quarter last year. During the same period last year, the company posted ($0.22) earnings per share. Equities analysts expect that Tempus AI, Inc. will post -1.38 earnings per share for the current year.

Institutional Trading of Tempus AI

A number of institutional investors have recently modified their holdings of the company. Truist Financial Corp boosted its stake in shares of Tempus AI by 5.8% during the 4th quarter. Truist Financial Corp now owns 3,532 shares of the company’s stock worth $209,000 after acquiring an additional 194 shares in the last quarter. Main Management ETF Advisors LLC increased its position in shares of Tempus AI by 1.0% in the fourth quarter. Main Management ETF Advisors LLC now owns 26,622 shares of the company’s stock valued at $1,572,000 after buying an additional 272 shares in the last quarter. Arkadios Wealth Advisors increased its position in shares of Tempus AI by 9.6% in the first quarter. Arkadios Wealth Advisors now owns 4,963 shares of the company’s stock valued at $224,000 after buying an additional 435 shares in the last quarter. EMC Capital Management acquired a new position in shares of Tempus AI during the 2nd quarter worth approximately $29,000. Finally, NewEdge Advisors LLC lifted its position in shares of Tempus AI by 1.3% during the 1st quarter. NewEdge Advisors LLC now owns 42,996 shares of the company’s stock valued at $1,944,000 after buying an additional 536 shares in the last quarter. 24.22% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the company. BTIG Research increased their price target on Tempus AI from $70.00 to $80.00 and gave the stock a “buy” rating in a research report on Thursday, August 20th. Wall Street Zen upgraded shares of Tempus AI from a “sell” rating to a “hold” rating in a report on Saturday, July 25th. Wolfe Research began coverage on shares of Tempus AI in a research report on Tuesday, June 2nd. They issued a “peer perform” rating for the company. Piper Sandler upgraded shares of Tempus AI from a “neutral” rating to an “overweight” rating and increased their price objective for the company from $56.00 to $76.00 in a research note on Tuesday, September 1st. Finally, Lake Street Capital lowered shares of Tempus AI to a “hold” rating in a report on Monday, July 20th. Eleven investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $69.33.

More Tempus AI News

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: CEO commentary outlining Tempus AI’s growth strategy and projected Medicare revenue has strengthened confidence that reimbursement expansion could provide a significant new revenue stream. Tempus AI Stock Roars Back 92% From July Low After CEO Lays Out Growth Plan
• Positive Sentiment: Morgan Stanley’s updated outlook reportedly incorporated additional reimbursement-driven revenue potential, helping fuel a sharp weekly advance in TEM shares and reinforcing the bullish growth narrative. Tempus AI Is Ripping 30% Higher This Week After Morgan Stanley Boosts Revenue Outlook
• Positive Sentiment: Trading momentum remains strong: shares have rebounded roughly 92% to 95% from the July low, with market capitalization moving above $14 billion. Above-average volume and elevated call-option activity indicate substantial speculative interest. Tempus AI Stock Is Soaring
• Neutral Sentiment: Analysts and market commentators are assessing whether the recent surge can continue. The rally has improved sentiment, but the sharp move also raises the risk of profit-taking and increased volatility. Strength Seen in Tempus
• Negative Sentiment: Zacks cautioned that recent earnings-estimate revision trends may not support another near-term advance, while brokerages maintain an average “Hold” rating. Tempus also remains unprofitable, making the stock particularly sensitive to valuation concerns and changes in growth expectations. Tempus AI Receives Average Hold Rating

Tempus AI Company Profile

Tempus AI, Inc is a healthcare technology company focused on applying artificial intelligence and data analytics to precision medicine. The company combines molecular testing, clinical data and machine learning to help physicians make more informed treatment decisions and support the development of new therapies.

Tempus provides genomic and diagnostic testing services, including testing intended to identify clinically relevant mutations and other biomarkers. Its technology platform also organizes and analyzes clinical and molecular data, while its AI-enabled tools are designed to assist healthcare professionals with patient care, research and workflow management.

The company serves healthcare providers, patients, pharmaceutical companies and biotechnology researchers, primarily in the United States.